Drug interactions in primary care: Impact of a new algorithm on risk determination

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 1, 2004, Pages 85-96

  Bergk, Verena ^b   Gasse, Christiane ^b   Rothenbacher, Dietrich ^b   Loew, Michael ^b   Brenner, Hermann ^b   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALLOPURINOL; ALPRAZOLAM; ANTILIPEMIC AGENT; ASPARAGINASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARBAMAZEPINE; CIMETIDINE; CLONIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPIPODOPHYLLOTOXIN; GLIBENCLAMIDE; LEVOTHYROXINE; METOPROLOL; PARACETAMOL; PAROXETINE; POTASSIUM; SIMVASTATIN; SOTALOL; SPIRONOLACTONE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; INFORMATION; LEUKEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; POPULATION; POTASSIUM DEPLETION; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; PUBLICATION; QT PROLONGATION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING; SEROTONIN SYNDROME; SIDE EFFECT;

AGED; ALGORITHMS; COHORT STUDIES; DRUG INTERACTIONS; HUMANS; MIDDLE AGED; PRIMARY HEALTH CARE; RISK;

EID: 3042658496     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.02.009     Document Type: Article

References (44)

1. East C., Alivizatos P.A., Grundy S.M., Jones P.H., Farmer J.A. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 318:1988;47-48
2. Kobashigawa J.A., Murphy F.L., Stevenson L.W., Moriguchi J.D., Kawata N., Kamjoo P., et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation. 82:(Suppl IV):1990;IV-281-IV-283
3. Jankel C.A., Speedie S.M. Detecting drug interactions a review of the literature. Ann Pharmacother. 24:1990;982-989
4. Björkman I.K., Fastbom J., Schmidt I.K., Bernsten C.B. the Pharmaceutical Care of the Elderly in Europe Research (PEER) Group. Drug-drug interactions in the elderly. Ann Pharmacother. 36:2002;1675-1681
5. Costa A.J. Potential drug interactions in an ambulatory geriatric population. Fam Pract. 8:1991;234-236
6. Bergendal L., Friberg A., Schaffrath A. Potential drug-drug interactions in 5, 125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci. 17:1995;152-157
7. Rosholm J.U., Bjerrum L., Hallas J., Worm J., Gram L.F. Polypharmacy and the risk of drug-drug interactions among Danish elderly. Dan Med Bull. 45:1998;210-213
8. Bjerrum L., Andersen M., Petersen G., Kragstrup J. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care. 21:2003;153-158
9. Jankel C.A., Fitterman L.K. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf. 9:1993;51-59
10. Gurwitz J.H., Field T.S., Harrold L.R., Rothschild J., Debellis K., Seger A.C., et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 289:2003;1107-1116
11. Gandhi T.K., Weingart S.N., Borus J., Seger A.C., Peterson J., Burdick E., et al. Adverse drug events in ambulatory care. N Engl J Med. 348:2003;1556-1564
12. FASS (Pharmaceutical Specialities in Sweden). Stockholm: LINFO Läkemedelsinformation AB (drug information); 2000. Available from: URL: http://www.fass.se. Accessed May 13, 2004
13. Merlo J., Liedholm H., Lindblad U., Björck-Linné A., Fält J., Lindberg G., et al. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999 cross sectional study. BMJ. 323:2001;427-428
14. Hamelin B.A., Bouayad A., Methot J., Jobin J., Desgagnes P., Poirier P., et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther. 67:2000;466-477
15. Nix D.E., Watson W.A., Lerner M.E., Frost R.W., Krol G., Goldstein H., et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther. 46:1989;700-705
16. Edwards I.R., Aronson J.K. Adverse drug reactions definitions, diagnosis, and management. Lancet. 356:2000;1255-1259
17. WHO Collaborating Centre for Drug Statistics Methodology (Norway). Anatomical Therapeutic Chemical (ATC) index with DDDs. 2002;The WHO Collaborating Centre, Oslo
18. Klasko R.K. DRUGDEX system. 1st ed. 2003;Thomson MICROMEDEX, Greenwood Village (CO)
19. Zimmermann R., Ehlers W., Walter E., Hoffrichter A., Lang P.D., Andrassy K., et al. The effect of bezafibrate on the fibrinolytic enzyme system and the drug interaction with racemic phenprocoumon. Atherosclerosis. 29:1978;477-485
20. Kantola T., Kivistö K.T., Neuvonen P.J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 64:1998;177-182
21. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78;902-7
22. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 341:1999;709-717
23. Brooks N., Cattell M., Pidgeon J., Balcon R. Unpredictable response to nifedipine in severe cardiac failure. BMJ. 281:1980;1324
24. Pennell D.J., Nunan T.O., O'Doherty M.J., Croft D.N. Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol [letter]. Lancet. 1:1984;463
25. Samanta A., Burden A.C. Fever, myalgia, and arthralgia in a patient on captopril and allopurinol [letter]. Lancet. 1:1984;679
26. Veehof L.J.G., Stewart R.E., Haaijer-Ruskamp F.M., Meyboom-de Jong B. The development of polypharmacy. A longitudinal study. Fam Pract. 17:2000;261-267
27. Bjerrum L., Sogaard J., Hallas J., Kragstrup J. Polypharmacy correlations with sex, age and drug regimen. Eur J Clin Pharmacol. 54:1998;197-202
28. Fuhr U., Weiss M., Kroemer H.K., Neugebauer G., Rameis H., Weber W., et al. Systematic screening for pharmacokinetic interactions during drug development. Int J Clin Pharmacol Ther. 34:1996;139-151
29. Thefeld W. Prevalence of diabetes mellitus in the adult German population [in German]. Gesundheitswesen. 61:(Suppl 2):1999;S85-89
30. Hermann-Kunz E. Incidence of allergic diseases in East and West Germany [in German]. Gesundheitswesen. 61:(Suppl 2):1999;S100-105
31. Gasse C., Hense H.W., Stieber J., Doring A., Liese A.D., Keil U. Assessing hypertension management in the community trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project, Augsburg 1984-1995. J Hum Hypertens. 15:2001;27-36
32. Dambro M.R., Kallgren A. Drug interactions in a clinic using Costar. Comput Biol Med. 18:1988;31-38
33. Mitchell G.W., Stanaszek W.F., Nichols N.B. Documenting drug-drug interactions in ambulatory patients. Am J Hosp Pharm. 36:1979;653-657
34. Kurfees J.K., Dotson R.L. Drug interactions in the elderly. Fam Pract. 25:1987;477-488
35. Wrenger E., Müller R., Moesenthin M., Welte T., Frölich J.C., Neumann K.H. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers analysis of 44 cases. BMJ. 327:2003;147-149
36. Schepkens H., Vanholder R., Billiouw J.M., Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone an analysis of 25 cases. Am J Med. 110:2001;438-441
37. Bates D.W., Cullen D.J., Laird N., Petersen L.A., Small S.D., Servi D., et al. Incidence of adverse drug events and potential adverse drug events implications for prevention. ADE Prevention Study Group. JAMA. 274:1995;29-34
38. Juurlink D.N., Mamdani M., Kopp A., Laupacis A., Redelmeier D.A. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 289:2003;1652-1658
39. Hamilton R.A., Briceland L.L., Andritz M.H. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy. 18:1998;1112-1120
40. Williams D., Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 41:2002;343-370
41. Tamblyn R., Huang A., Perreault R., Jacques A., Roy D., Hanley J., et al. The medical office of the 21st century (MOXXI) effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. CMAJ. 169:2003;549-556
42. Halkin H., Katzir I., Kurman I., Jan J., Malkin B.B. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther. 69:2001;260-265
43. Magnus D., Rodgers S., Avery A.J. GPs' views on computerized drug interaction alerts questionnaire survey. J Clin Pharm Ther. 27:2002;377-382
44. Glassman P.A., Simon B., Belperio P., Lanto A. Improving recognition of drug interactions benefits and barriers to using automated drug alerts. Med Care. 40:2002;1161-1171